The thesis

Mirum Pharmaceuticals is a biopharmaceutical firm developing treatments for rare conditions, with 735.0% year-over-year revenue growth. The company's conviction score is 53 out of 100, indicating moderate confidence. Analysts have a buy consensus rating, despite a negative price-to-earnings ratio of -7.6x. This setup is interesting due to the contrast between strong revenue growth and poor margins, including a gross margin of 8136.0% and a net margin of -14024.0%

Why now

The current risk-on rotation underway makes this the right moment to pay attention to Mirum Pharmaceuticals, as it is a direct beneficiary of this market force. With a recent macro signal indicating a +20 driver, the company's stock may be poised for movement

What to watch

Over the next quarter, watch for updates on LIVMARLI's trial progress and the company's ability to improve its margins. Additionally, monitor the company's revenue growth and analyst consensus rating, as any changes to these metrics could significantly impact the stock's performance

Key risks

Valuation risk is a major concern, as the company's DCF intrinsic value is -$3449, indicating potential overvaluation. Execution risk is also a factor, as the company's lead experimental drug, LIVMARLI, is still undergoing trials. Additionally, the company's poor margins, including a net margin of -14024.0%, pose a significant risk to its long-term viability